Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, G. Chen et al.|Annals of Oncology|2015Cited by 467
Formononetin ameliorates IL‑13‑induced inflammation and mucus formation in human nasal epithelial cells by activating the SIRT1/Nrf2 signaling pathwayJuanjuan Huang, Aihua Xie|Molecular Medicine Reports|2021Cited by 26